Page 20 - JCTR-11-1

Journal of Clinical and
Translational Research Cannabinoids for cannabis use disorder

for the treatment of cannabis withdrawal syndrome: A case 2012;18(32):4897-4905.
report. J Clin Pharm Ther. 2013;38(2):162-164.
doi: 10.2174/138161212802884825
doi: 10.1111/jcpt.12018
35. Pertwee RG. The diverse CB and CB receptor pharmacology
2
1
33. Hermann D, Sartorius A, Welzel H, et al. Dorsolateral of three plant cannabinoids: Delta9‐tetrahydrocannabinol,
prefrontal cortex N-acetylaspartate/total creatine (NAA/ cannabidiol and delta9‐tetrahydrocannabivarin. Br J
tCr) loss in male recreational Cannabis users. Biol Psychiatry. Pharmacol. 2008;153(2):199-215.
2007;61(11):1281-1289.
doi: 10.1038/sj.bjp.0707442
doi: 10.1016/j.biopsych.2006.08.027
36. Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane
34. Hermann D, Schneider M. Potential protective effects of Handbook for Systematic Reviews of Interventions Version 6.4.
cannabidiol on neuroanatomical alterations in cannabis United Kingdom: Cochrane; 2023. Available from: https://www.
users and psychosis: A critical review. Curr Pharm Des. training.cochrane.org/handbook [Last accessed on 2024 Aug 1].

Volume 11 Issue 1 (2025) 14 doi: 10.36922/jctr.24.00066